- Home
- BIAF vs NXTC Comparison
BIAF vs NXTC Comparison
Compare BIAF & NXTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- NXTC
- Stock Information
- Founded
- BIAF 2014
- NXTC 2015
- Country
- BIAF United States
- NXTC United States
- Employees
- BIAF N/A
- NXTC N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- NXTC Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- NXTC Health Care
- Exchange
- BIAF Nasdaq
- NXTC Nasdaq
- Market Cap
- BIAF 12.2M
- NXTC 13.9M
- IPO Year
- BIAF 2022
- NXTC 2019
- Fundamental
- Price
- BIAF $0.29
- NXTC $0.46
- Analyst Decision
- BIAF Hold
- NXTC Strong Buy
- Analyst Count
- BIAF 1
- NXTC 2
- Target Price
- BIAF N/A
- NXTC $3.50
- AVG Volume (30 Days)
- BIAF 11.2M
- NXTC 338.3K
- Earning Date
- BIAF 08-13-2025
- NXTC 07-31-2025
- Dividend Yield
- BIAF N/A
- NXTC N/A
- EPS Growth
- BIAF N/A
- NXTC N/A
- EPS
- BIAF N/A
- NXTC N/A
- Revenue
- BIAF $8,809,228.00
- NXTC N/A
- Revenue This Year
- BIAF N/A
- NXTC N/A
- Revenue Next Year
- BIAF $20.00
- NXTC N/A
- P/E Ratio
- BIAF N/A
- NXTC N/A
- Revenue Growth
- BIAF 78.40
- NXTC N/A
- 52 Week Low
- BIAF $0.16
- NXTC $0.22
- 52 Week High
- BIAF $2.99
- NXTC $1.82
- Technical
- Relative Strength Index (RSI)
- BIAF 50.96
- NXTC 45.99
- Support Level
- BIAF $0.22
- NXTC $0.45
- Resistance Level
- BIAF $0.46
- NXTC $0.49
- Average True Range (ATR)
- BIAF 0.04
- NXTC 0.07
- MACD
- BIAF 0.01
- NXTC -0.01
- Stochastic Oscillator
- BIAF 30.51
- NXTC 4.63
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases and NC181, for Alzheimer's disease.